Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada
Mondher Mtibaa,1 Subhajit Gupta,2 Madhusubramanian Muthukumar,2 Jessica Marvel,3 Harneet Kaur,2 Ryotaro Ishikawa,3 Ron Olivenstein4 1Novartis Pharmaceuticals Canada Inc., Dorval, Quebec, Canada; 2Novartis Healthcare Private Limited, Hyderabad, India; 3Novartis Pharma AG, Basel, Switzerland; 4McGill...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-12-01
|
| Series: | ClinicoEconomics and Outcomes Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/cost-effectiveness-of-once-daily-single-inhaler-indacaterol-acetate-gl-peer-reviewed-fulltext-article-CEOR |
| _version_ | 1818742286894235648 |
|---|---|
| author | Mtibaa M Gupta S Muthukumar M Marvel J Kaur H Ishikawa R Olivenstein R |
| author_facet | Mtibaa M Gupta S Muthukumar M Marvel J Kaur H Ishikawa R Olivenstein R |
| author_sort | Mtibaa M |
| collection | DOAJ |
| description | Mondher Mtibaa,1 Subhajit Gupta,2 Madhusubramanian Muthukumar,2 Jessica Marvel,3 Harneet Kaur,2 Ryotaro Ishikawa,3 Ron Olivenstein4 1Novartis Pharmaceuticals Canada Inc., Dorval, Quebec, Canada; 2Novartis Healthcare Private Limited, Hyderabad, India; 3Novartis Pharma AG, Basel, Switzerland; 4McGill University, Montreal, Quebec, CanadaCorrespondence: Mondher MtibaaNovartis Pharmaceuticals Canada Inc., 385 Bouchard Blvd., Dorval, Quebec, H9S 1A9, CanadaTel +1 514 631-6775 ext. 1367Email mondher.mtibaa@novartis.comPurpose: We evaluated the cost-effectiveness of high-dose indacaterol acetate (IND)/glycopyrronium bromide (GLY)/mometasone furoate (MF) (150/50/160 μg, once daily) compared with high-dose salmeterol/fluticasone (SAL/FLU; 50/500 μg, twice daily)+tiotropium (TIO; 5 μg, once daily) (SAL/FLU+TIO) and with high-dose SAL/FLU (50/500 μg, twice daily) for the treatment of inadequately controlled moderate-to-severe asthma.Patients and Methods: A Markov model estimated the incremental cost-effectiveness ratio of treatment with high-dose IND/GLY/MF compared with SAL/FLU+TIO and high-dose IND/GLY/MF compared with SAL/FLU. The model included three health states (day-to-day symptoms without exacerbations, day-to-day symptoms with exacerbations, and death) with a 4-week cycle length. A lifetime time horizon was used. Exacerbation rates and utility values were derived from ARGON and IRIDIUM clinical trials. Canadian dollars (CAD$, 2020) were applied.Results: IND/GLY/MF was the less costly and more effective treatment strategy compared with SAL/FLU+TIO and SAL/FLU in the base-case analyses. IND/GLY/MF had lower costs (CAD $33,501 versus CAD $50,907) and higher quality-adjusted life-years (QALYs) (18.37 versus 18.06 QALYs) compared with SAL/FLU+TIO. Compared with SAL/FLU, IND/GLY/MF had lower costs (CAD $33,408 versus CAD $36,577) and higher QALYs (19.33 versus 19.04 QALYs). IND/GLY/MF was the most cost-effective option in all scenarios tested.Conclusion: IND/GLY/MF was cost-effective at a willingness-to-pay threshold of CAD $50,000/QALY in patients with uncontrolled, moderate-to-severe asthma versus SAL/FLU+TIO and SAL/FLU in the base case and all scenarios tested.Keywords: moderate to severe asthma, indacaterol acetate, glycopyrronium bromide, mometasone furoate, cost-effectiveness, health care payer perspective, Canada, uncontrolled asthma |
| first_indexed | 2024-12-18T02:10:07Z |
| format | Article |
| id | doaj.art-2f208fcdacca47f9a9f22c49a8440957 |
| institution | Directory Open Access Journal |
| issn | 1178-6981 |
| language | English |
| last_indexed | 2024-12-18T02:10:07Z |
| publishDate | 2021-12-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | ClinicoEconomics and Outcomes Research |
| spelling | doaj.art-2f208fcdacca47f9a9f22c49a84409572022-12-21T21:24:30ZengDove Medical PressClinicoEconomics and Outcomes Research1178-69812021-12-01Volume 1395796771163Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in CanadaMtibaa MGupta SMuthukumar MMarvel JKaur HIshikawa ROlivenstein RMondher Mtibaa,1 Subhajit Gupta,2 Madhusubramanian Muthukumar,2 Jessica Marvel,3 Harneet Kaur,2 Ryotaro Ishikawa,3 Ron Olivenstein4 1Novartis Pharmaceuticals Canada Inc., Dorval, Quebec, Canada; 2Novartis Healthcare Private Limited, Hyderabad, India; 3Novartis Pharma AG, Basel, Switzerland; 4McGill University, Montreal, Quebec, CanadaCorrespondence: Mondher MtibaaNovartis Pharmaceuticals Canada Inc., 385 Bouchard Blvd., Dorval, Quebec, H9S 1A9, CanadaTel +1 514 631-6775 ext. 1367Email mondher.mtibaa@novartis.comPurpose: We evaluated the cost-effectiveness of high-dose indacaterol acetate (IND)/glycopyrronium bromide (GLY)/mometasone furoate (MF) (150/50/160 μg, once daily) compared with high-dose salmeterol/fluticasone (SAL/FLU; 50/500 μg, twice daily)+tiotropium (TIO; 5 μg, once daily) (SAL/FLU+TIO) and with high-dose SAL/FLU (50/500 μg, twice daily) for the treatment of inadequately controlled moderate-to-severe asthma.Patients and Methods: A Markov model estimated the incremental cost-effectiveness ratio of treatment with high-dose IND/GLY/MF compared with SAL/FLU+TIO and high-dose IND/GLY/MF compared with SAL/FLU. The model included three health states (day-to-day symptoms without exacerbations, day-to-day symptoms with exacerbations, and death) with a 4-week cycle length. A lifetime time horizon was used. Exacerbation rates and utility values were derived from ARGON and IRIDIUM clinical trials. Canadian dollars (CAD$, 2020) were applied.Results: IND/GLY/MF was the less costly and more effective treatment strategy compared with SAL/FLU+TIO and SAL/FLU in the base-case analyses. IND/GLY/MF had lower costs (CAD $33,501 versus CAD $50,907) and higher quality-adjusted life-years (QALYs) (18.37 versus 18.06 QALYs) compared with SAL/FLU+TIO. Compared with SAL/FLU, IND/GLY/MF had lower costs (CAD $33,408 versus CAD $36,577) and higher QALYs (19.33 versus 19.04 QALYs). IND/GLY/MF was the most cost-effective option in all scenarios tested.Conclusion: IND/GLY/MF was cost-effective at a willingness-to-pay threshold of CAD $50,000/QALY in patients with uncontrolled, moderate-to-severe asthma versus SAL/FLU+TIO and SAL/FLU in the base case and all scenarios tested.Keywords: moderate to severe asthma, indacaterol acetate, glycopyrronium bromide, mometasone furoate, cost-effectiveness, health care payer perspective, Canada, uncontrolled asthmahttps://www.dovepress.com/cost-effectiveness-of-once-daily-single-inhaler-indacaterol-acetate-gl-peer-reviewed-fulltext-article-CEORmoderate to severe asthmaindacaterol acetateglycopyrronium bromidemometasone furoatecost-effectivenesshealth care payer perspectivecanadauncontrolled asthma |
| spellingShingle | Mtibaa M Gupta S Muthukumar M Marvel J Kaur H Ishikawa R Olivenstein R Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada ClinicoEconomics and Outcomes Research moderate to severe asthma indacaterol acetate glycopyrronium bromide mometasone furoate cost-effectiveness health care payer perspective canada uncontrolled asthma |
| title | Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada |
| title_full | Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada |
| title_fullStr | Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada |
| title_full_unstemmed | Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada |
| title_short | Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada |
| title_sort | cost effectiveness of once daily single inhaler indacaterol acetate glycopyrronium bromide mometasone furoate in patients with uncontrolled moderate to severe asthma in canada |
| topic | moderate to severe asthma indacaterol acetate glycopyrronium bromide mometasone furoate cost-effectiveness health care payer perspective canada uncontrolled asthma |
| url | https://www.dovepress.com/cost-effectiveness-of-once-daily-single-inhaler-indacaterol-acetate-gl-peer-reviewed-fulltext-article-CEOR |
| work_keys_str_mv | AT mtibaam costeffectivenessofoncedailysingleinhalerindacaterolacetateglycopyrroniumbromidemometasonefuroateinpatientswithuncontrolledmoderatetosevereasthmaincanada AT guptas costeffectivenessofoncedailysingleinhalerindacaterolacetateglycopyrroniumbromidemometasonefuroateinpatientswithuncontrolledmoderatetosevereasthmaincanada AT muthukumarm costeffectivenessofoncedailysingleinhalerindacaterolacetateglycopyrroniumbromidemometasonefuroateinpatientswithuncontrolledmoderatetosevereasthmaincanada AT marvelj costeffectivenessofoncedailysingleinhalerindacaterolacetateglycopyrroniumbromidemometasonefuroateinpatientswithuncontrolledmoderatetosevereasthmaincanada AT kaurh costeffectivenessofoncedailysingleinhalerindacaterolacetateglycopyrroniumbromidemometasonefuroateinpatientswithuncontrolledmoderatetosevereasthmaincanada AT ishikawar costeffectivenessofoncedailysingleinhalerindacaterolacetateglycopyrroniumbromidemometasonefuroateinpatientswithuncontrolledmoderatetosevereasthmaincanada AT olivensteinr costeffectivenessofoncedailysingleinhalerindacaterolacetateglycopyrroniumbromidemometasonefuroateinpatientswithuncontrolledmoderatetosevereasthmaincanada |